Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel antibiotic therapies to combat serious and life-threatening infections. The company was founded in 2015 and is headquartered in Allentown, Pennsylvania.
The urgent need for new and effective antibiotics has become increasingly clear in recent years, as bacterial infections have become more resistant to existing treatments. Acurx Pharmaceuticals is working to address this critical issue by developing antibiotics that target the underlying mechanisms of bacterial resistance.
Acurx's lead product candidate is ibezapolstat, an oral, first-in-class antibiotic designed to treat Clostridioides difficile (C. diff) infection. C. diff is a bacterial infection that can cause severe diarrhea and colitis, and is a leading cause of hospital-acquired infections. Ibezapolstat targets the DNA polymerase enzyme, which is essential for bacterial replication, and has shown promising results in preclinical and early-stage clinical trials.
In addition to its focus on C. diff infection, Acurx is also developing a pipeline of antibiotics to treat other serious bacterial infections, including gram-negative bacteria and methicillin-resistant Staphylococcus aureus (MRSA).
Acurx Pharmaceuticals is committed to advancing its pipeline through rigorous clinical development and regulatory approval processes. The company has a team of experienced scientists and clinicians who bring decades of expertise in antibiotic research and development.
The company has also received recognition for its innovative approach to antibiotic development, including being named one of the Top 10 Infectious Disease Companies to Watch in 2021 by PharmaTech Outlook magazine.
As the global need for new antibiotics continues to grow, Acurx Pharmaceuticals is well-positioned to make a significant impact in the fight against serious bacterial infections. With a commitment to scientific excellence, patient safety, and antibiotic stewardship, Acurx is poised to become a leading player in the antibiotic development space.
Comentários